7Baggers
Quarterly
Annual
    Unit: USD2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-03-31 
      
    		                   
      assets
    		                   
      current assets:
    		                   
      cash and cash equivalents
    		235,807,000 169,065,000 171,945,000 501,409,000 306,267,000 464,714,000 132,149,000 316,231,000            
      marketable securities
    		317,679,000 433,410,000 192,648,000 19,031,000 59,840,000 101,547,000 223,185,000 229,983,000            
      trade receivable
    		352,449,000 328,342,000  252,952,000 168,637,000 156,769,000              
      inventory
    		106,561,000 91,281,000  74,864,000 64,058,000 58,329,000              
      prepaid expenses
    		100,360,000 104,891,000 88,838,000 61,698,000 48,871,000               
      other current assets
    		61,485,000 44,096,000 33,946,000 34,427,000 18,907,000               
      total current assets
    		1,174,341,000 1,171,085,000 876,254,000 944,381,000 666,580,000 900,696,000 603,406,000 708,285,000 362,562,000 474,446,000 328,281,000 423,170,000 474,352,000 227,373,000 272,339,000 182,980,000 227,602,000 114,673,000 53,169,000 
      property and equipment
    		15,727,000 14,534,000 14,690,000 10,409,000 10,885,000 11,258,000 9,340,000 8,802,000 8,979,000 8,933,000 8,152,000 7,460,000 7,433,000 7,157,000 6,248,000 4,891,000 3,792,000 2,936,000 43,000 
      intangible assets
    		75,112,000 55,910,000 56,438,000 56,968,000 57,501,000 58,226,000 39,087,000 39,811,000 40,535,000 41,259,000          
      other assets
    		121,069,000 130,188,000 129,830,000 119,437,000 110,927,000 32,979,000 33,966,000 23,251,000 9,706,000 4,073,000 2,493,000 1,351,000 24,000 36,000 11,000 64,000 43,000 32,000  
      total assets
    		1,386,249,000 1,371,717,000 1,077,212,000 1,131,195,000 845,893,000 1,003,159,000 686,975,000 782,015,000 424,255,000 532,669,000 344,264,000 439,087,000 490,908,000 245,080,000 290,012,000 195,091,000 239,290,000 126,135,000 60,191,000 
      liabilities and shareholders’ deficit
    		                   
      current liabilities:
    		                   
      accounts payable
    		64,149,000 56,202,000 51,683,000 49,437,000 60,002,000 64,571,000 48,476,000 43,976,000 17,044,000 29,703,000 14,071,000 11,562,000 13,502,000 8,210,000 10,752,000 4,658,000 4,027,000 9,051,000 4,022,000 
      accrued expenses and other current liabilities
    		545,307,000 457,412,000 420,019,000 350,339,000 276,630,000 268,720,000 165,784,000 126,267,000 118,123,000 76,770,000          
      current portion of mandatorily redeemable preferred shares
    		62,500,000 62,500,000 62,500,000 62,500,000 62,500,000 62,500,000 62,500,000 46,875,000 31,250,000 15,625,000          
      total current liabilities
    		671,956,000 576,114,000 534,202,000 462,276,000 399,132,000 395,791,000 276,760,000 217,118,000 166,417,000 122,098,000 66,173,000 47,206,000 44,669,000 23,693,000 19,534,000 15,264,000 12,755,000 16,865,000 15,442,000 
      long-term debt
    		764,983,000 634,106,000 626,720,000 619,267,000 274,138,000 270,756,000 267,458,000 264,135,000            
      liability related to sale of future royalties
    		388,027,000 377,998,000 367,645,000 357,655,000 347,384,000 339,020,000 328,350,000 318,594,000 160,805,000 151,454,000 144,111,000 136,799,000 129,487,000 124,332,000  111,919,000 106,282,000   
      mandatorily redeemable preferred shares
    		180,213,000 162,994,000 155,737,000 144,333,000 133,091,000 122,119,000 111,591,000 119,456,000 127,771,000 136,404,000 103,646,000 99,268,000 94,890,000       
      derivative liabilities
    		110,129,000      14,190,000 1,940,000            
      obligation to perform r&d services
    		29,972,000 36,016,000 50,571,000 47,155,000 55,353,000 60,530,000              
      other long-term liabilities
    		46,527,000 41,782,000 12,236,000 16,666,000 17,501,000 18,698,000 20,815,000 14,590,000 4,728,000 105,000 68,000 43,000 43,000 44,000 2,043,000 2,095,000 1,423,000 1,454,000 19,000 
      total liabilities
    		2,191,807,000 1,838,130,000 1,760,221,000 1,662,402,000 1,242,489,000 1,221,314,000 1,019,164,000 935,833,000 459,721,000 410,711,000 351,688,000 320,111,000 304,167,000 148,069,000 139,092,000 129,278,000 120,460,000 18,319,000 39,833,000 
      commitments and contingencies
    		                   
      contingently redeemable non-controlling interests
    		  60,000,000 60,000,000 60,000,000 60,000,000 60,000,000 60,000,000            
      shareholders’ deficit:
    		                   
      common shares, no par value; 200,000,000 shares authorized as of june 30, 2022 and december 31, 2021; 71,111,071 and 66,933,531 shares issued and outstanding as of june 30, 2022 and december 31, 2021, respectively
    		2,181,398,000                   
      additional paid-in capital
    		167,021,000 129,580,000 169,656,000 165,052,000 142,405,000 123,731,000 98,938,000 103,419,000 91,773,000 92,129,000 83,523,000 67,496,000 58,717,000 46,538,000 40,104,000 36,358,000 32,982,000 28,194,000 20,371,000 
      accumulated other comprehensive loss
    		-5,811,000 -2,398,000                  
      accumulated deficit
    		-3,143,541,000 -2,702,154,000 -2,585,755,000 -2,386,572,000 -2,214,756,000 -2,004,137,000 -1,739,169,000 -1,521,433,000 -1,326,244,000 -1,145,310,000 -972,373,000 -823,109,000 -716,942,000 -505,872,000 -443,568,000 -388,818,000 -327,377,000   
      total shareholders’ deficit attributable to biohaven pharmaceutical holding company ltd.
    		-800,933,000 -462,286,000 -739,380,000 -587,976,000 -453,877,000 -275,976,000 -390,370,000             
      non-controlling interests in consolidated subsidiaries
    		-4,625,000 -4,127,000 -3,629,000 -3,231,000 -2,719,000 -2,179,000 -1,819,000             
      total shareholders' deficit
    		-805,558,000 -466,413,000 -743,009,000 -591,207,000 -456,596,000 -278,155,000 -392,189,000             
      total liabilities and shareholders’ deficit
    		1,386,249,000 1,371,717,000  1,131,195,000 845,893,000 1,003,159,000              
      derivative liability
    		 9,120,000 13,110,000 15,050,000 15,890,000 14,400,000    650,000 37,690,000 36,795,000 35,078,000      223,000 
      common shares, no par value; 200,000,000 shares authorized as of march 31, 2022 and december 31, 2021; 70,540,802 and 66,933,531 shares issued and outstanding as of march 31, 2022 and december 31, 2021, respectively
    		 2,112,686,000                  
      trade receivables
    		  308,269,000     79,522,000 44,796,000 4,337,000          
      inventories
    		  80,608,000    39,563,000 20,131,000 8,970,000 4,582,000          
      equity method investment
    		      1,176,000 1,866,000 2,473,000 3,958,000 5,338,000 7,106,000 9,099,000 10,514,000 11,414,000 7,156,000 7,853,000 8,494,000 4,511,000 
      liabilities and shareholders' deficit
    		                   
      shareholders' deficit:
    		                   
      common shares, no par value; 200,000,000 shares authorized as of december 31, 2021 and 2020; 66,933,531 and 60,436,876 shares issued and outstanding as of december 31, 2021 and december 31, 2020, respectively
    		  1,676,792,000                 
      accumulated other comprehensive income
    		  -73,000 82,000 280,000 409,000 314,000 251,000            
      total liabilities and shareholders' deficit
    		  1,077,212,000    686,975,000  424,255,000           
      common shares, no par value; 200,000,000 shares authorized as of september 30, 2021 and december 31, 2020; 65,473,332 and 60,436,876 shares issued and outstanding as of september 30, 2021 and december 31, 2020, respectively
    		   1,633,462,000                
      common shares, no par value; 200,000,000 shares authorized as of june 30, 2021 and december 31, 2020; 65,240,458 and 60,436,876 shares issued and outstanding as of june 30, 2021 and december 31, 2020, respectively
    		    1,618,194,000               
      prepaid expenses and other current assets
    		     119,337,000 88,398,000 62,418,000 47,735,000 37,288,000 11,554,000 6,596,000 8,613,000 9,966,000 8,090,000 14,795,000 10,150,000 10,467,000 883,000 
      common shares, no par value; 200,000,000 shares authorized as of march 31, 2021 and december 31, 2020; 65,066,468 and 60,436,876 shares issued and outstanding as of march 31, 2021 and december 31, 2020, respectively
    		     1,604,021,000              
      trade receivables, net of allowance
    		      120,111,000             
      common shares, no par value; 200,000,000 shares authorized as of december 31, 2020 and 2019; 60,436,876 and 44,197,549 shares issued and outstanding as of december 31, 2020 and december 31, 2019, respectively
    		      1,249,547,000             
      liabilities and shareholders’ equity
    		                   
      shareholders’ equity
    		                   
      common shares, no par value; 200,000,000 shares authorized as of september 30, 2020 and december 31, 2019; 59,707,780 and 52,385,283 shares issued and outstanding as of september 30, 2020 and december 31, 2019, respectively
    		       1,205,384,000            
      total shareholders’ equity (deficit) attributable to biohaven pharmaceutical holding company ltd.
    		       -212,379,000            
      non-controlling interests
    		       -1,439,000            
      total shareholders' equity
    		       -213,818,000   -7,424,000    150,920,000     
      total liabilities and shareholders' equity
    		       782,015,000   344,264,000         
      cash
    		        261,061,000 428,239,000 316,727,000 416,574,000 465,739,000 217,407,000 264,249,000 168,185,000 217,452,000 104,206,000 52,286,000 
      common shares, no par value; 200,000,000 shares authorized as of june 30, 2020 and december 31, 2019; 59,525,565 and 52,385,283 shares issued and outstanding as of june 30, 2020 and december 31, 2019, respectively
    		        1,199,005,000           
      total shareholders’ deficit
    		        -35,466,000           
      common shares, no par value; 200,000,000 shares authorized as of march 31, 2020 and december 31, 2019; 58,387,948 and 52,385,283 shares issued and outstanding as of march 31, 2020 and december 31, 2019, respectively
    		         1,175,139,000          
      total shareholders’ equity
    		         121,958,000  118,976,000 186,741,000 97,011,000  65,813,000 118,830,000 107,816,000  
      total liabilities and shareholders’ equity
    		         532,669,000  439,087,000 490,908,000 245,080,000  195,091,000 239,290,000 126,135,000  
      liabilities and shareholders' equity
    		                   
      accrued expenses
    		          52,102,000 35,644,000 31,167,000 15,483,000 8,782,000 10,606,000 8,728,000 7,814,000 6,931,000 
      shareholders' equity:
    		                   
      common shares, no par value; 200,000,000 shares authorized as of december 31, 2019 and 2018; 52,385,283 and 44,197,549 shares issued and outstanding as of december 31, 2019 and december 31, 2018, respectively
    		          881,426,000         
      shareholders’ equity:
    		                   
      common shares, no par value; 200,000,000 shares authorized as of september 30, 2019 and december 31, 2018; 52,217,684 and 44,197,549 shares issued and outstanding as of september 30, 2019 and december 31, 2018, respectively
    		           874,589,000        
      common shares, no par value; 200,000,000 shares authorized as of june 30, 2019 and december 31, 2018; 51,501,614 and 44,197,549 shares issued and outstanding as of june 30, 2019 and december 31, 2018, respectively
    		            844,966,000       
      common shares, no par value; 200,000,000 shares authorized as of march 31, 2019 and december 31, 2018; 44,282,994 and 44,197,549 shares issued and outstanding as of march 31, 2019 and december 31, 2018, respectively
    		             556,345,000      
      non-recourse debt related to sale of future royalties
    		              117,515,000     
      warrant liability
    		                  1,234,000 
      common shares, no par value; 200,000,000 shares authorized as of december 31, 2018 and 2017; 44,197,549 and 36,057,748 shares issued and outstanding as of december 31, 2018 and december 31, 2017, respectively
    		              554,384,000     
      total liabilities, convertible preferred shares and shareholders' equity
    		              290,012,000     
      common shares, no par value; 200,000,000 shares authorized as of september 30, 2018 and december 31, 2017; 40,261,750 and 36,057,748 shares issued and outstanding as of september 30, 2018 and december 31, 2017, respectively
    		               418,273,000    
      common shares, no par value; 200,000,000 shares authorized as of june 30, 2018 and december 31, 2017; 40,094,291 and 36,057,748 shares issued and outstanding as of june 30, 2018 and december 31, 2017, respectively
    		                413,225,000   
      common shares, no par value; 200,000,000 shares authorized as of march 31, 2018 and december 31, 2017; 38,607,017 and 36,057,748 shares issued and outstanding as of march 31, 2018 and december 31, 2017, respectively
    		                 367,730,000  
      restricted cash
    		                   
      deferred offering costs
    		                  2,399,000 
      deferred tax assets
    		                  9,000 
      liabilities, convertible preferred shares and shareholders’ equity
    		                   
      notes payable, net of discount
    		                  4,489,000 
      contingent equity liability
    		                  22,313,000 
      notes payable to related parties
    		                  602,000 
      series a convertible preferred shares, no par value; 11,242,172 shares authorized as of march 31, 2017 and december 31, 2016; 9,358,560 and 4,948,369 shares issued and outstanding as of march 31, 2017 and december 31, 2016, respectively; aggregate liquidation preference of 86,951 and 45,976 as of march 31, 2017 and december 31, 2016, respectively
    		                  73,900,000 
      common shares, no par value; 38,000,000 shares authorized as of march 31, 2017 and december 31, 2016; 13,121,000 and 13,088,500 shares issued and outstanding as of march 31, 2017 and december 31, 2016, respectively
    		                  20,296,000 
      total liabilities, convertible preferred shares and shareholders’ equity
    		                  60,191,000 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.